
GABA Therapeutics: Pioneering fast, safe, non-addictive anxiety and depression solutions with GRX-917.
GABA Therapeutics was founded with the core mission of developing innovative treatments for anxiety, depression, and chronic pain that are fast-acting, safe, and non-addictive. The company’s flagship product, GRX-917, leverages the production of endogenous neurosteroids and inhibits NLRP3 inflammation to offer a transformative solution for neuropsychiatric, neurological, and autoimmune disorders. GABA Therapeutics aims to address the unmet needs in mental health treatment with minimal side effects and no addiction potential.
Notable figures affiliated with GABA Therapeutics include Richard Farrell. The company has achieved significant milestones, including preparing GRX-917 for Phase 3 registration studies in anxiety. By focusing on mechanisms that induce natural neurosteroid production, GABA Therapeutics has made a substantial impact in the field of mental health, offering hope for safer and more effective treatments for anxiety and depression.

Psy Therapeutics
psythx.com

Gain Therapeutics

Neurogastrx
neurogastrx.com

NeuroTherapia
neurotherapia.com

Zena Therapeutics

NeuroTherapeutics Pharma

Gilgamesh Pharmaceuticals

Neuronascent
neuronascent.com

Libra Therapeutics

Evecxia
evecxia.com

Neuraly
neuralymed.com

Delix Therapeutics
GlobeStar Therapeutics

NeyroblastGX
neyroblastgx.com

Therini Bio
therinibio.com
Companies similar to Gaba Therapeutics include Psy Therapeutics, Gain Therapeutics, Neurogastrx and NeuroTherapia.
Gaba Therapeutics was founded in 2018.
Gaba Therapeutics' headquarters is located in Delaware, US.
Gaba Therapeutics' most recent funding round was for $15.5M (USD) in September 2019.
As of Sep 23, 2019, Gaba Therapeutics has raised a total of $15.5M (USD).
Gaba Therapeutics has 35 employees as of Feb 5, 2024.